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Background: Autoinflammatory diseases (AIDs) are a relatively new family of 
disorders defined about 19 years ago. Some of them are hereditary and some 
are not.The names given to these diseases do not follow any systematic 
guidelines and sometimes the same disorder carries several names. 
Aims: The aim of this study is to refine the definition of the autoinflammatory 
diseases and to provide some conventions for their naming. We have focused 
our attention mainly on monogenetic AIDs. 
Methods: Delphi technique which enables consensus among a group of 
experts through Internet and mail communication and questionnaires - was 
employed. After achieving 100% consensus among 6 members of a steering 
committee, the questionnaire containing the AID definitions and the agreed-
upon conventions, were sent to 26 physicians and researchers working in the 
field of AIDs in order to gain broader support for the committee's proposals. 
Results: The committee proposed the following definition for AIDs 
"Autoinflammatory diseases are clinical disorders caused by defect(s) or 
dysregulation of the innate immune system, characterized by recurrent or 
continuous inflammation (elevated acute phase reactants-APR) and the lack 
of a primary pathogenic role for the adaptive immune system (autoreactive T-
cells or autoantibody production)”. Several rules were defined for guiding the 
naming of these diseases among which are: abandoning eponyms and 
preferring the name of the gene over its encoded protein. 
Conclusions: The new definition for AIDs allows inclusion of clinical 
disorders mainly associated with defects in the innate immune system. The 
new conventions propose names with clinical meaning and in some cases 
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Taxonomy is the science of naming. It is relevant to all fields of biology in which we 
name plants, animals, objects and diseases. In medicine, naming of diseases or 
syndromes has a special importance since it can give some clue about the nature of 
the clinical condition, its clinical features, pathogenesis and sometimes even an 
approach to treatment. Naming is also important for accurate and effective 
communication among different health disciplines. However, medical disorders have 
not been named in a standard way [1]. Physicians, who treat patients with a 
particular disorder or face a new clinical condition, are often the first to propose a 
name for the disease. Expert working groups may later revise the names to improve 
their usefulness.  
Names of medical disorders are often derived from one or a combination of the 
following sources: genetic basis or biochemical defect; geographic spread; or by 
eponyms. The main drawback of many names is the lack of a clinical meaning that 
could help the novice to understand the origin of the disease or recognize its clinical 
characteristics .  
The autoinflammatory diseases (AIDs) are a group of medical disorders, derived from 
defects or dysregulation of the innate immune system [2]. This family of diseases 
was established in 1999 following the identification of the genes underlying two 
recurrent fever syndromes: familial Mediterranean fever (FMF) [3,4] and TNF-
receptor-associated periodic syndrome (TRAPS) [5]. Over the last 18 years, more 
and more diseases have been classified amongst this group of disorders, some of 
which may not fit well with the classical definition of the AIDs. Moreover, many of 
them were given names with no systematic guidelines or rules. In some cases, the 
same disease carries several names (Table 1) [6-50]. This has led to a chaotic 
situation in naming these clinical disorders and has called for a better standardization 
of this field. This need is accentuated by recent progress in next generation 
sequencing techniques (NGS), which have led to an increasing capability to identify 
new genes and new syndromes, expanding the spectrum of AIDs.  
Indeed, following the International Society for Systemic Autoinflammatory Diseases 
(ISSAID) meeting in Lausanne, in 2013, a mandate was given to one of us (E B-C) to 
undertake a preliminary consensus based exercise for the following aims: a. to refine 
the definition of the "autoinflammatory diseases". b. to provide some rules and new 
proposals for naming this current group of clinical conditions and those that will be 
identified in the future.  
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In order to find the different definitions proposed for AIDs over the years, we 
searched the MEDLINE/PubMed Central® (PMC) from 1998 to January 2016, using 
the MESH search term: “autoinflammatory diseases” (supplementary Figure S1). In 
order to find the names used for each AID, we took one of their current names as 
depicted in Table 1 and searched for papers where they were first reported. Then, we 
searched for reviews on these items to find additional synonymous names Table 1 is 
based on a list of AIDs published by one of the authors (IT) [51], properly integrated 
and updated during the consensus process and finally approved  by all the steering 
committee members. It focused - mainly - on monogenic disorders. 
For choosing the best definition for AIDs and the most appropriate name for each 
AID, we have used the Delphi technique, which enables consensus among a group 
of experts through mail communication [52]. The Delphi method is essentially a 
series of questionnaires involving several steps, each of which is based on the 
results of the previous step. The process stops when consensus of at least 80% of 
the participants on each item is reached. [53] 
An ad hoc steering committee of 6 clinicians and researchers from 6 different 
countries who are working in the field of autoinflammation was established. 
The first Delphi questionnaire was built through sending broad and open-ended 
questions in order to elicit different opinions from the panelists about the current 
definitions and names of AIDs.  
Once received, the replies from the panelists were analyzed to generate a series of 
statements that were employed as the basis for follow up questionnaires that were 
sent back to the individual participants. In each subsequent questionnaire, the 
panelists were also provided with the overall results (responses) of the previous 
questionnaire from all the members. After achieving 100% consensus among the 
steering committee members, the questionnaire containing the AID definitions and 
the agreed-upon names of AIDs were sent to 26 physicians and researchers working 
in the field of AIDs around the world. They were identified in the Paediatric 
Rheumatology International Trials Organization (PRINTO) mailing list through their 
high active participation in the Eurofever registry [54, 55]. The aim of this step was to 
gain broader support for the committee's proposals and to consider changes once a 
name was rejected by or was not acceptable to more than 80% of the participants of 
the large group of AIDs experts. Delphi survey implementation was conducted by 
PRINTO [56]. 
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AIDs proposed definition 
The literature review disclosed 536 papers of which only 7 specifically dealt with the 
definitions of AIDs [5, 57- 62] (supplementary Figure S1). The first definition for AIDs 
was proposed by the NIH group in 1999 [5]. This definition was as follows: "The 
autoinflammatory syndromes are systemic disorders characterized by apparently 
unprovoked inflammation in the absence of high-titer autoantibodies or antigen-
specific T lymphocytes". This definition was based mainly upon the two diseases 
whose related genes had then been identified: FMF and TRAPS [3- 5]. Since in both 
diseases the flares appeared mostly spontaneous, the definition included the word 
"unprovoked". The definition stresses the lack of involvement of the adaptive immune 
system in these disorders, since no autoantibodies or autoreactive T-cells were 
involved.  
Seven years later McGonagle and McDermott suggested another definition: "AIDs 
are characterized by self-directed inflammation, whereby local factors at sites 
predisposed to disease lead to activation of innate immune cells, including 
macrophages and neutrophils, with resultant target tissue damage. For example, 
disturbed homeostasis of canonical cytokine cascades (as in the periodic fevers), 
aberrant bacterial sensing (as in Crohn's disease), and tissue micro-damage 
predispose one to site-specific inflammation that is independent of adaptive immune 
responses" [57]. The authors proposed that immunological diseases ought to be 
conceived as a continuum with “pure monogenic autoinflammatory diseases” at one 
end and “pure monogenic autoimmune diseases” at the other. This definition is 
relatively complex, but explicitly invokes innate immunity and widens the spectrum of 
AIDs.  
Later, several other definition or refinement were proposed [58-61]. In a recent study, 
de Jesus et al. provide an outstanding classification of AIDs strictly based on their 
pathophysiology [62]. However, the authors do not propose a new definition for the 
AIDs.  
Given the proliferation of AID definitions, with sometimes conflicting concepts, the 
steering committee agreed to adopt the first and original definition with minor 
modifications: "Autoinflammatory diseases are clinical disorders caused by defect(s) 
or dysregulation of the innate immune system, characterized by recurrent or 
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continuous inflammation (elevated - APR) and the lack of a primary pathogenic role 
for the adaptive immune system (autoreactive T-cells or autoantibody production).”  
This definition emphasizes the essential fact that the disorders are caused by defects 
in the innate immune system and are continuous or recurrent. The word 
"unprovoked" has been deleted since in many cases there is a trigger for the acute 
flares.  
The steering committee is aware that diseases such as PLCG2-associated antibody 
deficiency and immune dysregulation (PLAID) or Heme - oxidised IRP2 ubiquitin 
ligase1 (HOIL-1) deficiency, traditionally included among the AIDs, will not be part of 
this group, because they may contain components of the adaptive immune system 
such as autoantibodies [63]. The "Interferonopathies" include some disorders also 
manifesting autoantibodies. However, the consensus seemed to be that for disorders 
like Aicardi-Goutières Syndrome (AGS) in which nucleic acid sensing is primarily 
intracellular, autoantibodies usually play a minor role in disease pathogenesis, and 
thus the autoinflammatory designation may still be appropriate. In their recent review 
Rodero and Crow propose that “type I interferonopathies can reasonably be 
considered as autoinflammatory in origin, with ‘spill-over’ into autoimmunity in some 
cases” [64]. The group of "typical" autoimmune diseases includes disorders 
affecting primarily or only the adaptive system such as systemic lupus erythematosus 
(SLE), Hashimoto thyroiditis, DNAse deficiencies and autoimmune 
lymphoproliferative syndrome (ALPS). 
AIDs proposed nomenclature 
The current names for AIDs bring several problems and issues, which called for a 
new approach and nomenclature modification; many AIDs possess more than a 
single name (FMF - 7 different names, TRAPS - 3, etc) (Table 1 and Supplementary 
Table S1); different clinical presentations are associated with similar sequence 
alterations in the same gene eg. Muckle-Wells syndrome(MWS), familial cold 
autoinflammatory syndrome (FCAS) and Neonatal onset multisystem inflammatory 
disease (NOMID) are associated with NLRP3 gene whereas FMF and pyrin-
associated autoinflammation with neutrophilic dermatosis (PAAND) are associated 
with MEFV gene. In addition discussion arose about several topics briefly 
summarized herein: In naming AIDs should we use the name of the gene or that of 
the encoded protein (MEFV or pyrin)? Should we include typical clinical features or 
just genetic attributes? Should historical names be retained?  
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Following more than 6 cycles of Delphi questionnaires and oral discussions among 
the 6 members of the steering committee  with further involvement of the 26 AIDs 
experts around the world - a consensus of at least 80% was reached for the 
nomenclature of the diseases shown in Tables 1 and 2. 
General conventions (Table 3) 
The proposed names for AIDs have been established according to the rules and 
suggestions outlined in Table 3. 
In many diseases the course of the disease is episodic with frequent attacks and 
attack-free intervals. When the frequency of the attacks is relatively regular (as is the 
case with Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) and 
sometimes with mevalonate kinase deficiency (MKD) we preferred the term 
"periodic". When the attacks do not have a regular pattern, we suggested the word 
"recurrent”.  
In the past, both terms, “periodic” and “recurrent”, have been used interchangeably 
but now the term "periodic” remained in the names of 3 conditions only; Cryopyrin-
associated periodic fever syndrome (CAPS),TRAPS and PFAPA. In TRAPS, we 
decided to keep the original name "periodic", although its flares are recurrent rather 
than periodic. In CAPS, we propose a new name (NLRP3-AID) which does not 
contain the word “periodic since the attacks are not periodic”. Thus, we strongly 
suggest using the more appropriate terms in naming disorders in the future. 
As a general rule, we tried to use names containing etio-pathological (genetic) 
features of the disease and where appropriate or possible, to add a significant clinical 
characteristic of the syndrome. Thus, we left the name TRAPS without change, since 
it consists of its genetic etiology (mutations in TNFRSF1A gene) and characteristic 
clinical features [periodic (recurrent) fever]. On the other hand, the name hyper IgD 
syndrome (HIDS) was abandoned since it is an absolutely inaccurate name: serum 
IgD is not always elevated in these patients while it may be elevated in other AIDs. 
Therefore, this name was replaced by MKD based upon our knowledge of the gene 
involved, mevalonate kinase (MVK). In this way, a physician or researcher who 
approaches these names for the first time may have immediately a basic 
understanding of the disorder and sometimes even a clue to the potential treatment. 
In cases where the choice was between using the name of the gene associated with 
the disease or the protein encoded by the gene, we preferred the name of the gene 
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over that of the protein unless the former was meaningless. A typical example is the 
choice of NLRP3 gene over cryopyrin despite the tendency of some clinicians to stay 
with the former term CAPS. Fortunately, in many cases the name of the gene and the 
encoded protein are the same (MK, NOD2) making the choice easier. However, this 
was not the case with the MEFV gene and pyrin where the name of the protein was 
chosen, as will be discussed later. 
In our proposals for new taxonomy of AIDs, we tried to avoid the use of names of 
persons (such as Nakajo Nishimura syndrome) or geographical distribution of the 
disease (such as Guadeloupe fever) or names with unusual meaning (such as 
"Cherubism").  
Specific names (Table 1 and Supplementary Table S1)  
In the case of CAPS – which encompasses three clinical entities (FCAS, MWS, 
NOMID/CINCA), the committee has proposed using a single name; NLRP3-
associated autoinflammatory disease (NLRP3-AID). Since the various disorders 
reflect different levels of phenotypic severity of the same disease, it was suggested to 
add the adjectives: mild, moderate, and severe phenotypes, instead of using the 
historical names FCAS, MWS and CINCA/NOMID, respectively.  
In familial cold autoinflammatory syndrome 2 (FCAS2) (Guadeloupe fever), different 
families present with different phenotypes [36]. Since the gene associated with the 
disease (NLRP12) is known, the committee decided to name this syndrome NLRP12-
associated autoinflammatory disease (NLRP12-AID).  
In the case of MEFV-associated diseases, the question raised was as follows: should 
we use the old name FMF or "atypical FMF" for all syndromes associated with 
mutations in the MEFV gene even if they have totally different clinical 
manifestations? Alternatively, should we find a different way to classify these 
disorders? The committee chose to use a general name (as a "roof ") "pyrin-
associated autoinflammatory diseases" (PAAD) which includes all diseases 
associated with pyrin defects or MEFV mutations. Under this general term, there are 
subtypes of disorders with different names, according to their clinical presentation or 
genetic features, such as: PAAND, FMF, etc. [65] (Figure 1). Although it is preferred 
using the name of the gene over the name of the encoded protein, in the case of 
FMF, the protein pyrin was chosen rather than the MEFV gene. One of the reasons 
was that the name MEFV, which was coined to denote its association with familial 
Mediterranean fever, is no longer accurate, since it may lead to totally different AIDs, 
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such as PAAND and CRMO-like disorder. In addition, we did not change the name of 
familial Mediterranean fever (FMF), although sometimes it is neither familial nor 
restricted to the Mediterranean basin and in rare cases, it may even be without a 
documented fever. Most members of the steering committee thought that FMF is a 
well-known and defined entity and that changing the name would cause discomfort 
and confusion among the AID clinical community. The name FMF remained under 
the "roof" of "pyrin-associated autoinflammatory diseases" (PAAD) as a clinical entity 
which is restricted mainly to Middle Eastern patients or to patients elsewhere, whose 
disease is associated with exon 10 mutations [66].  
Regarding Mevalonate kinase disorders the committee suggested leaving MKD as a 
general name with the option of adding "mild" for those with hyper IgD syndrome and 
"severe" for those with mevalonic aciduria (67). In rare cases, where the patient with 
MKD has also retinitis pigmentosa or porokeratosis, it is suggested to mention these 
manifestations in addition to MKD (Table 1, and Supplementary Table S1 ).  
The name NOD2-associated granulomatous disease was chosen by the committee 
for the three phenotypes: Blau syndrome, familial sarcoidosis and familial Crohn's 
disease. Since all these syndromes are characterized by granulomas, this feature 
was included in the name. Nevertheless, an option was offered to add IBD in cases 
where the intestines are the main site of involvement eg. NOD2-associated 
granulomatous IBD (formerly called familial Crohn's disease). 
The name for CRMO was replaced by the name chronic non-bacterial osteomyelitis 
CNO. The reason for that was the presence of many cases where the disease was 
neither recurrent nor multifocal. Furthermore, the new name emphasizes the main 
feature of the disease, non-bacterial osteomyelitis. Since this clinical entity may be 
associated with mutations in various genes, it is optional to add the name of the gene 
when it is known. For example in case the gene involved is LPIN2 it can be marked 
as LPIN2-CNO (previously known as Majeed’s syndrome). In adults, patients with 
sporadic CNO are usually diagnosed with SAPHO, a symptom complex of Synovitis, 
Acne, Pustulosis, Hyperostosis, and Osteitis [68]. 
Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
syndrome (CANDLE syndrome) gained a new name: PSMB8-PRAAS - where 
PSMB8 stands for Proteasome Subunit Beta 8 and PRAAS for  PRoteasome-
Associated Autoinflammatory Syndrome. This name replaces also the eponym 
Nakajo Nishimura syndrome, and JMP which stands for Joint contractures, Muscle 
atrophy, microcytic anemia and Panniculitis-induced lipodystrophy. The name 
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PSMB8-PRAAS consists of the genetic etio-pathology of the disorder but does not 
include any clinical feature of the disease.  
CARD14-associated disease is usually characterized by psoriasis with or without 
pustulosis. Therefore, the name was refined to be CARD14-associated psoriasis. 
Since the 3 variants of IL-10 deficiency are always associated with inflammatory 
bowel disease, the committee proposed a single name as IL-10 deficiency-
associated IBD. 
The names; deficiency of the interleukin 1 receptor antagonist (DIRA), deficiency of 
the interleukin 36 receptor antagonist (DITRA), pyogenic arthritis, pyoderma 
gangrenosum, and acne (PAPA) and PFAPA remained unchanged since they 
already conform to our naming conventions. However, the letter P in the abbreviation 
"PAPA" now stands for the name of the gene PSTPIP1 rather than “Pyogenic” and, 
therefore, the new name is "PSTPIP1-associated arthritis, pyoderma gangrenosum 
and acne" (PAPA). 
The name "Cherubism" was derived from the Biblical "cherub" (plural cherubim) who 
has four faces of different species and several pairs of wings,. For most physicians 
this name does not mean much and therefore, the committee proposed the name 
SH3BP2 deficiency with multilocular cystic disease of the mandibles (SDCM). This 
name gives the etio-pathologic basis of the syndrome with the main clinical feature of 
fibrous dysplasia of the mandibles. 
Finally, the name “Schnitzler syndrome” also remained as an historical one, since its 
pathogenesis is still obscure and its relationship with NLRP3 mutations has not been 
established [69]. A proposal to convert the name of the syndrome to a clinical 
description: "late onset gammopathy with recurrent urticaria and fever" (LOGRUF) 
did not gain support from most of the committee members. 
Discussion  
The definition of autoinflammatory diseases has changed over the years in order to 
accommodate the new diseases discovered since 1999 – the year the term was first 
proposed [2, 5, 57-61]. Widening the scope and spectrum of definition of AIDs 
resulted in the inclusion of disorders with additional defects in the adaptive immune 
system such as PLAID or HOIL-1 deficiency. Most defects in the immune system 
may affect primarily either the innate or the adaptive arm. However, it is becoming 
increasingly obvious that the innate immune system almost always has an effect on 
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the adaptive system. This leads to the situation that there are disorders that do not fit 
neatly into the "pure" autoinflammatory or autoimmune categories, and reside 
actually in a "grey zone" between these two groups. In order to include these 
disorders with the typical AIDs under the same "rafter", Peckham et al. offered the 
term "Auto-inflammatory-immune diseases" [70]. We believe that this new name may 
lead to confusion since all the disorders caused or related to defects in the immune 
system can be classified under this wide term with no clear categorization. The 
interferonopathies are clinical disorders caused by defects in the innate response, 
leading to inflammation after DNA sensing. The activation of cells of the adaptive 
immunity is a secondary effect of this condition and seems to play a minor role in 
their pathogenesis. Therefore, they may create the bridge which fits the concept that 
the autoinflammatory diseases, and the autoimmune diseases are actually in the 
same spectrum of immune disorders. This continuum model is further supported by 
the recent discovery of the innate lymphoid cells (ILCs). These cells are defined by 
differential expression of cell-surface markers and are activated by neuropeptides, 
cytokines and other alarmins [71]. Their specialized distribution in lymphoid and non-
lymphoid tissues, coupled with their functional heterogeneity, has provoked a 
fundamental reassessment of how they integrate innate and adaptive immune 
responses. 
As already mentioned - many of the current names of AIDs were not appropriate, 
inaccurate or lack any clinical meaning. Therefore, an attempt to establish new 
conventions for naming them was really needed.  
The conventions (Table 3), and the ensuing proposals (Table 1, and Supplementary 
Table S1), call for using the name of the gene associated with the disease when it is 
known rather than the encoded protein. In these cases, demonstration of functional 
significance of the identified sequence alteration is mandatory.The main advantage 
of using the name of the gene is that such a name gives the physician a clue about 
the pathogenesis of the disease and sometimes even about a potential treatment. 
Moreover, it may allow definite diagnosis using genetic testing. However, it should be 
borne in mind that including the gene in the name of the disease may pose a problem 
in cases where the clinical features of the patient are compatible with a certain 
diagnosis while no expected sequence alteration is found. Thus, the main drawback 
of using the name of the gene is that definite diagnosis can be made only by genetic 
testing.  
Page 12 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
13 
 
In cases where the clinical features and the genetic testing results are in accord, the 
name is appropriate and the diagnosis is correct and definite. When there is a clearly 
pathogenic mutation but the clinical features are completely incompatible with the 
expected diagnosis, one should consider a different disease with a different name. 
This situation is illustrated by the case of the MEFV mutation S242R, which causes 
neutrophilic dermatosis. The name of this disease is not "FMF" or "atypical FMF" 
despite the fact that there are MEFV mutations - but "pyrin-associated 
autoinflammation with neutrophilic dermatosis (PAAND)". Similar approach may be 
applied in the case of PSTPIP1 with the new mutation and different clinical 
presentation [72]. We suggest here a "roof" name : PSTPIP1-associated 
autoinflammatory diseases with two subtypes: PAPA and PAMI (PSTPIP1-
associated myeloid-related proteinemia inflammatory syndrome). However, we 
cannot add this approach to Table 1 since it was not discussed in the Delphi 
questionnaires among the large group of participants 
When the clinical features are typical for a certain disease ( for example FMF) and 
yet no genetic support for this diagnosis is found, one can denote this medical 
condition as an FMF-like disease. However, a better choice would be to leave the 
case as an undefined AID until mutations in other genes are found or additional 
explanations for the disease are given. The reason is that clinical features typical for 
one AID may be associated with mutations in different genes. For example, in 
arecent  report, Karacan et al. described two Turkish families in whom 4 patients 
presented with typical clinical features of FMF [73]. Genetic analysis performed in 
these patients failed to show MEFV mutations. However, total exon sequencing 
revealed that two patients were homozygous for mutations in MVK and the two other 
patients carried mutations in the TNFRSF1A gene. These cases illustrate the 
difficulties in making a diagnosis of AID based upon clinical features only and justify 
the proposal to use the gene in naming AIDs wherever it is known. 
 The way we proposed naming CAPS and FCAS 2 namely NLRP3-associated 
autoinflammatory disease (NLRP3-AID) and NLRP12-AID respectively may pave the 
way for naming future disorders to be discovered or identified among the other 
members of the large family of NOD–like receptors (NLRs).. Similarly, PSMB8-
PRAAS, the name which was proposed to replace CANDLE syndrome, JMP and 
NNS, may also serve as an example for naming additional proteasome associated 
diseases to be discovered, just by changing their number. In fact, Brehm et al. 
recently described several cases that carry mutations in PSMA3 (encodes α7), 
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PSMB4 (encodes β7), PSMB9 (encodes β1i), and proteasome maturation protein 
(POMP) [74]. 
Unfortunately, the current study did not include  many other monogenic AIDs such as 
those associated with ADA2, NLRC4, NLRP1 genes or X-linked inhibitor of apoptosis 
(XIAP) deficiency and (SLAM)-associated protein (SAP) deficiency (75). The reason 
is that we limited ourselves mainly to the basic list reported by Toiutou et al.(51). 
However, we hope that the conventions we propose herein may help modifying 
names of additional diseases - old and new – when, they do not follow the rules 
suggested. 
For this project we used the Delphi technique which allowed discussion via an ad hoc 
web-based system developed by the PRINTO staff under the supervision of NR who 
has an extensive expertise in consensus formation methodologies. The PRINTO 
system allowed remote interaction between the participants who had the possibility to 
share written comments with the other participants in a transparent and traceable 
way. A limitation of the current work was that for lack of funding we could not conduct 
a formal nominal group technique (NGT) which is a guided face-to-face discussion 
and interaction, among small groups of experts. However, the additional discussion 
of the ad hoc steering committee consensus proposal by another group of 26 
worldwide experts in the field of AIDs further strengthens these proposals. 
In conclusion, the currently proposed rules for nomenclatures of AIDs are expected 
to allow a better organization of these groups of immune diseases. However, 
taxonomy is a dynamic process and some of the proposed names may be changed 
in the future as we gain a better knowledge about their pathogenesis. The proposed 
taxonomy may gain a broader consensus following an effective communication with 
other societies such as the International Union of Immunological Societies Expert 
Committee (IUIS).  
 
  
Page 14 of 71
https://mc.manuscriptcentral.com/ard





































































All authors (EBC, MG, AG, DLK, HJL, IT, NR) contributed equally to the planning and 
conduct of the study. Their placement in the authors’ list is dictated by the alphabetic 
order of their family names. 
The first version of the present manuscript was written by EBC, MG and NR, and 
then revised critically by all the remaining co-authors (AG, DLK, HJL, IT). 
 
Funding 
The development and coordination of the Delphi survey has been funded with the 
research budgets of Istituto Giannina Gaslini; no external entity such as 




For EBC, MG, AG, DLK, HJL, IT: Nothing to disclose for this manuscript. 
NR received honoraria for consultancy of speaker’s bureau from the following 
pharmaceutical companies since last 5 years: Abbott, AbbVie, Amgen, Biogenidec, 
Astellas, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer, BMS, CD-
Pharma,Celgene, CrescendoBio, EMD Serono, Hoffman-La Roche, Italfarmaco, 
Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Rewind Arms, R-
Pharma, Sanofi Aventis, Servier, Sinergie, Takeda, Vertex, UCB Biosciences GmbH. 
The Gaslini Hospital, which is the public Hospital where NR works as full time public 
employee, has received contributions from the following industries:  
 Abbott, BMS, "Francesco Angelini", GlaxoSmithKline (GSK), Hoffman-La Roche, 
Italfarmaco, Janssen, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Sobi, 
Page 15 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
16 
 
Xoma, Wyeth. This money has been reinvested for the research activities of the 
hospital in a fully independent manner without any committment with third parties. 
 
Additional participants to the Delphi study 
Ivona Aksentijevich, Jordi Anton, Juan I Arostegui, Karyl S. Barron, Luca Cantarini, 
Fatma Dedeoglu, Erkan Demirkaya, Joost Frenkel, Veronique Hentgen, Michael 
Hofer, Isabelle Koné-Paut, Jasmin B. Kuemmerle-Deschner, Avi Livneh, Alberto 
Martini, Laura Obici, Seza Ozen, Dorota Rowczenio, Ricardo Russo, Yael Shinar, 
Natasa Toplak, Marielle van Gijn have no conflicts of interest to declare. 
Dirk Foell has received grant support from Novartis and Pfizer, and honoraria from 
Sobi, Chugai-Roche, Novartis and Pfizer 
Philip J. Hashkes has acted as consultant and speaker for Novartis and consultant 
for Neovii. 
Yosef Uziel has received Grant / Research Support from Novartis, has acted as 
consultant for Novartis, and has received speaker’s bureau from Abbvie, Neopharm, 
Novartis and Roche. 
Tilmann Kallinich has received speaker’s bureau from Novartis, Sobi and Roche, and 
a research grant from Novartis.  
Ronald Laxer has acted as consultant for Lilly and Sanofi 
 
  
Page 16 of 71
https://mc.manuscriptcentral.com/ard


































































1. Beil M, Ben-Chetrit E. Taxonomy of auto-inflammatory diseases: time 
to consider changing some names. Clin Exp Rheumatol 2013;31(3 
Suppl 77):3-5.  
 
2. Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic 
autoinflammatory diseases define new pathways in human innate 
immunity and inflammation. Nat Immunol 2017; 18: 832– 842 .  
 
3. International FMF Consortium: Ancient missense mutations in a new 
member of the RoRet gene family are likely to cause familial 
Mediterranean fever. Cell 1997; 90:797-807. 
 
4. French FMF Consortium: A candidate gene for familial Mediterranean 
fever. Nat Genet 1997;17:25-31. 
 
 
5. McDermott M F, Aksentijevich I, Galon J, et al. Germline Mutations in 
the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, 
Define a Family of Dominantly Inherited Autoinflammatory Syndromes 




6. Siegal S (1945). "Benign paroxysmal peritonitis". Ann Intern Med 
1945; 23 (2): 234 – 247 
 
7. Reiman HA . "Periodic disease. Probable syndrome including periodic 
fever, benign paroxysmal peritonitis, cyclic neutropenia and 
intermittent arthralgia". J Am Med Assoc 1948; 136 (4): 239 – 244.  
 
8. Cattan R, Mamou H. 14 Cases of periodic disease, 8 of which are 
complicated by kidney diseases. Bull Mem Soc Med Hop Paris. 
1951;67:1104–1110  
  
9.  Heller H, Sohar E, Sherf L. Familial Mediterranean fever. AMA Arch 
Intern Med 1958;102:50 – 71 
 
10. Ehrenfeld E N, Eliakim M, Rachmilewitz M, Recurrent polyserositis 
(familial mediterranean fever; Periodic disease): A report of fifty-five 
cases. The Am Journal of Med 1961; 3: 107-123 
 
11. Saatci U, Ozen S, Bakkaloglu A, et al.Familial Mediterranean fever: a 
misnomer? Lancet. 1994;343(8895):485. 
 
12. Masters SL, Lagou V , Jéru I et al. Pyrin Associated Autoinflammation 
with Neutrophilic Dermatosis (PAAND), Familial autoinflammation 
with neutrophilic dermatosis reveals a regulatory mechanism of pyrin 
activation. Science Translational Medicine 2016; 8 : 332-345 
 
13. Williamson L M, Hull D, Mehta R, et al. Familial hibernian fever. Quart 
J Med, 1982,  51; 469 –480 
Page 17 of 71
https://mc.manuscriptcentral.com/ard

































































14. Mulley J, Saar K, Hewitt G et al.. Gene localization for an autosomal 
dominant familial periodic fever to 12p13 Am J Hum Genet 1998; 62: 
884–889 
 
15. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene 
encoding mevalonate kinase cause hyper-IgD and periodic fever 
syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22 
: 178 – 181. 
 
16. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding 
mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic 
fever syndrome. Nat Genet 1999; 22 (2): 175 –177. 
 
17. van der Meer JW, Vossen JM, Radl J, et 
al.Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. 
Lancet 1984; 1 (8386): 1087–1090. 
 
18. Frenkel J, Houten SM, Waterham HR et al. Mevalonate kinase 
deficiency and Dutch type periodic fever. Clin Exp Rheumatol. 
2000;18(4):525-532 
 
19. Prieur AM, Griscelli C Arthropathy with rash, chronic meningitis, 
neurological changes and arthritis. J Pediatr 1981; 99: 79-83. 
20. Muckle TJ. Urticaria, deafness, and amyloidosis: a new heredo-
familial syndrome. Quart J Med. 1962 ; 31: 235 – 248 
 
21. Kile, R. L., Rusk, H. A. A case of cold urticaria with unusual family 
history. J Am Med Assoc 1940; 114: 1067-1068 
 
22. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene 
encoding a putative pyrin-like protein causes familial cold 
autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 
2001; 29 (3): 301–305 
 
23. Blau EB. Familial granulomatous arthritis, iritis, and rash. Pediatr. 
1985;107(5):689 - 693 
 
24. James DG. A comparison of Blau's syndrome and sarcoidosis. 
Sarcoidosis. 1994;11(2):100-1 
 
25. McGovern DP, van Heel DA, Ahmad T, et al. NOD2 (CARD15), the 
first susceptibility gene for Crohn's disease. Gut. 2001;49:752–754. 
 
26.  Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory 
disease with deficiency of the interleukin-1–receptor antagonist. N 
Engl J Med 2009; 360: 2426–2437. 
 
27. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor 
antagonist deficiency and generalized pustular psoriasis. N Engl J 
Med 2011;365 (7):620–628 
 
28. Majeed, H; Kalaawi, M; Mohanty, D et al. Congenital 
dyserythropoietic anemia and chronic recurrent multifocal 
Page 18 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
19 
 
osteomyelitis in three related children and the association with Sweet 
syndrome in two siblings. J Pediatrics 1989;115: 730 – 734. 
 
29. Ferguson P J, Chen S, Tayeh M K, et al.. Homozygous mutations in 
LPIN2 are responsible for the syndrome of chronic recurrent 
multifocal osteomyelitis and congenital dyserythropoietic anaemia 
(Majeed syndrome) J Med Genet 2005;42:551–557. 
 
30. Keipert JA, Campbell PE. Recurrent hyperostosis of the clavicles: an 
undiagnosed syndrome. Aust Paediatr J 1970; 6 (1):97–104. 
 
31. Giedion A, Holthusen W, Masel LF, et al. Subacute and chronic 
‘‘symmetrical’’ osteomyelitis. Ann Radiol (Paris) 1972;15(3):329 – 342 
 
32.  Fuchs-Telem D,  Sarig O,  van Steensel M A M et al. Familial 
Pityriasis Rubra Pilaris Is Caused by Mutations in CARD14 Am J Hum 
Genet 2012 ;91: 163–170 
 
33. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations 
in CARD14. Am J Hum Genet 2012;90:784-795  
 
34. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease 
and mutations affecting the interleukin-10 receptor. N Engl J Med. 
2009;361(21):2033 – 2045. 
 
35. Glocker EO, Frede N, Perro M, et al. Infant colitis-it’s in the genes. 
Lancet. 2010;376 (9748):1272 
 
36. Jeru I, Duquesnoy P, Fernandes-Alnemri T et al. Mutations in 
NALP12 cause hereditary periodic fever syndromes. PNAS, 2008 
:105 (5): 1614 –1619 
 
37. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal 
dominant disorder of pyogenic sterile arthritis, pyoderma 
gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 
1997;72:611–615 
 
38. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt 
binding to PTP PEST and are responsible for PAPA syndrome, an 
autoinflammatory disorder. Hum. Mol. Genet. 2002;11:961–969 
 
39. Liu Y, Ramot Y, Torrelo A et al: Mutations in proteasome subunit beta 
type 8 cause chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperature with evidence of genetic and 
phenotypic heterogeneity. Arthritis Rheum. 2012; 64: 895-907 
 
40. Agarwal AK, Xing C, DeMartino GN et al. PSMB8 encoding the beta5i 
proteasome subunit is mutated in joint contractures, muscle atrophy, 
microcytic anemia, and panniculitis-induced lipodystrophy syndrome. 
Am J Hum Genet 2010; 87: 866-872 
 
41. Arima K, Kinoshita A, Mishima H, et al: Proteasome assembly defect 
due to a proteasome subunit beta type 8 (PSMB8) mutation causes 
the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc 
Natl Acad Sci U S A. 2011, 108: 14914 - 14919 
Page 19 of 71
https://mc.manuscriptcentral.com/ard

































































42. Schnitzler L. Lésions urticariennes chroniques permanentes 
(érythème pétaloïde?) Cas cliniques No 46 B, J Dermatol Angers 
1972 ; Abstract 46 
 
43. Tyson T K, Edwards F L. Periodic fever syndrome in children. J 
Pediatr 1999; 135: 1– 5 
 
44. Marshall GS, Edwards KM, Butler J, et al. Syndrome of periodic fever, 
pharyngitis, and aphthous stomatitis. J Pediatr 1987;110:43 - 46 
 
45. Ombrello M J, , Remmers E F, Sun G et al. Cold Urticaria, 
Immunodeficiency, and Autoimmunity Related to PLCG2 Deletions N 
Engl J Med 2012; 366:330-338 
 
46.  Wang K, Kim C, Bradfield J, et al. Whole-genome DNA/RNA 
sequencing identifies truncating mutations in RBCK1 in a novel 
Mendelian disease with neuromuscular and cardiac involvement. 
Genome Medicine 2013; 5 (7): 67-74 
 
47. Ueki Y, Tiziani V, Santanna C. et al. Mutations in the gene encoding 
c-Abl-binding protein SH3BP2 cause cherubism. Nat 
Genet2001;28:125 –126 
 
48. Jones, W. A. Familial Multilocular Cystic Disease of the Jaws. 
American J Cancer 1933;17 (4): 946-950 
 
49. Jones, W. A. Gerrie, J. Pritchard, J. Cherubism-familial fibrous 
dysplasia of the jaws. J bone joint surgery1950;32 (3): 334–347. 
 
50. Jaffe H L. Giant cell reparative granuloma traumatic bone cyst, fibrous 
(fibro-osseous) dysplasia of jaw bones. Oral Surg 1953;6:159-175 
 
51. Touitou I. Inheritance of autoinflammatory diseases: shifting 
paradigms and nomenclature. J Med Genet 2013;50:349–359 
 
 
52. Ruperto N, Meiorin S, Iusan S M, et al. Consensus procedures and 
their role in pediatric rheumatology. Curr rheumatol reports 
2008;10:142-146. 
 
53. Pill J, The Delphi method: Substance, context, a critique and an 
annotated bibliography. Socio-Economic Planning Sciences. 1971; 5: 
57-71  
 
54. Toplak N, Frenkel J, Ozen S et al. for the Paediatric Rheumatology 
International Trials Organisation (PRINTO). Eurotraps and Eurofever 
Projects. An International registry on Autoinflamatory diseases: the 
Eurofever experience. Ann Rheum Dis 2012;71:1177-1182. 
 
55. Federici S, Sormani M, Ozen S et alfor the Paediatric Rheumatology 
International Trials Organisation (PRINTO) and Eurofever Project. 
Evidence-based provisional clinical classification criteria for 
Page 20 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
21 
 
autoinflammatory periodic fevers. Ann Rheum Dis 2015; 2015;74:799 
– 805 
 
56. Ruperto N, Martini A, for the Paediatric Rheumatology International 
Trials Organisation (PRINTO). Networking in pediatrics: the example 
of the Pediatric Rheumatology International Trials Organisation 
(PRINTO). Archives Dis Child 2011; 96:596 - 601. 
 
 
57. McGonagle D, McDermott MF (2006) A proposed classification of the 
immunological diseases. PLoS Med 2006; 3 (8): e297:1242-1248 
 
58. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinﬂammatory 
disease reloaded: a clinical perspective. Cell 2010;140:784–790. 
 
59. Grateau G, Hentgen V, Stojanovic KS, et al. How should we approach 
classification of autoinflammatory diseases? Nat Rev Rheumatol 
2013; 9: 624-629  
 
60. Wekell P, Berg S, Karlsson A, et al. Towards an inclusive, congruent, 
and precise definition of autoinflammatory diseases. Frontiers in 
Immunol. 2017,Vol 8 Article 497. 
 
61. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigm 
and nomenclature. J Med Genet 2013; 50:349-359. 
 
62. de Jesus A. Canna S W, Liu Y, Goldbach-Mansky R., Molecular 
Mechanisms in Genetically Defined Autoinflammatory Diseases: 
Disorders of Amplified Danger Signaling. Annu Rev Immunol. 2015 ; 
33: 823–874.  
 
63. Milner J D. PLAID: A syndrome of complex patterns of disease and 
unique phenotypes.  J Clin Immunol. 2015; 35: 527– 530. 
 
 
64.  Rodero MP, Yanick J. Crow J Y, Type I interferon–mediated 
monogenic autoinflammation: The type I interferonopathies, a 
conceptual overview J Exp Med 2016; 213: 2527–2538 
 
3 
65. Shimizu M, Tone Y, Toga A, et al. Colchicine-responsive chronic 
recurrent multifocal osteomyelitis with MEFV mutations: a variant of 
familialMediterranean fever? Rheumatology, 2010; 49:2221– 2223 
 
66. Ben-Chetrit E, Ozdogan H. Can we make a diagnosis of 
autoinflammaty diseases based upon clinical features only? Clin Exp 
Rheumatol 2017, (35 Suppl) 108(6):16-18. 
 
Page 21 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
22 
 
67. Prietsch, V., Mayatepek, E., Krastel, H., et al. Mevalonate kinase 
deficiency: enlarging the clinical and biochemical spectrum. Pediatrics 
111: 258-261, 2003 
 
68. Hofmann S R, Kapplusch F, Girschick H J et al. Chronic Recurrent 
Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and 
Treatment. Curr Osteoporos Rep. 2017; 15(6): 542–554 
 
 
69. de Koning H D, van Gijn M E, Stoffels M, Myeloid lineage–restricted 
somatic mosaicism of NLRP3 mutations in patients with variant 
Schnitzler syndrome. J Allergy Clin Immunol 2015;135: 561-564. 
 
70. Peckham D, Scambler T, Savic S, et al. The burgeoning field of 
innate immune-mediated disease and autoinflammation. J Pathol 
2017; 241: 123 –139. 
  
71. Artis D, Spits H. The biology of innate lymphoid cells, Nature 2015; 
517:293-301  
 
72. Holzinger D, Fassl S K, de Jager W, et al, Single amino acid charge 
switch defines clinically distinct proline-serine-threonine phosphatase-
interacting protein 1 (PSTPIP1)–associated inflammatory diseases J 
Allegy clin immunol  2015;136:1337-1345 
 
73. Karacan I, Uğurlu S, Tolun A, et al. Other autoinflammatory disease 
genes in a FMF-prevalent population: A homozygous missense MVK 
mutation and a novel heterozygous TNFRSF1A mutation in two 
different Turkish families with clinical FMF. Clin Exp Rheumatol 2017, 
35 Suppl 108(6):75-81 
 
74. Brehm A, Liu Y, Sheikh A et al. Additive loss-of-function proteasome 
subunit mutations in CANDLE/PRAAS patients promote type I IFN 
production. J clin Invest 2015:125:4196 – 4211 
 
 
75. Rigaud S, Fondanèche MC, Lambert N et al. XIAP deficiency in 





Page 22 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
23 
 
Glossary - Abbreviations 
 
 
AGS - Aicardi-Goutières Syndrome 
 
AIDs - Autoinflammatory diseases 
 
AIMDs - Autoimmune diseases 
 
ALPS - Autoimmune lymphoproliferative syndrome 
 
 
APR - Acute phase reactant 
 
CANDLE - Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated 
temperature syndrome 
 
CAPS - Cryopyrin-associated periodic fever syndrome 
 
CARD - Caspase recruitment domain family member 
CINCA- Chronic infantile neurologic, cutaneous and articular syndrome  
CNO - Chronic non-bacterial osteomyelitis 
CRMO -Chronic recurrent multifocal osteomyelitis 
ADA2 - adenosine deaminase 2 
DIRA - Deficiency of the interleukin 1 receptor antagonist 
 
DITRA - Deficiency of the interleukin 36 receptor antagonist 
 
FCAS - Familial cold autoinflammatory syndrome  
FMF - Familial Mediterranean fever  
HIDS - Hyper-IgD with periodic fever syndrome 
 
HOIL -1 - Heme - oxidised IRP2 ubiquitin ligase 1 
 
IBD - Inflammatory bowel disease 
ISSAID - International society for systemic autoinflammatory diseases  
 
JMP - Joint contractures, muscle atrophy, microcytic anemia and panniculitis-induced 
lipodystrophy. 
LOGRUF - Late onset gammopathy with recurrent urticarial and fever 
MEFV - Mediterranean fever 
MK- Mevalonate kinase 
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MKD - Mevalonate kinase deficiency 
MVK - Mevalonate kinase 
MWS - Muckle-Wells syndrome; 
NALP 12- NACHT, LRR and PYD domains-containing protein 1 
NGS - New generation sequencing 
NLR - NOD-like receptor 
NLRC4 - NOD-like receptor with CARD containing 4 
NLRP - NOD-like receptor with LRR (Leucine rich repeat), and PYD domain;  
NOD - Nucleotide-binding oligomerization domain;  
NOMID - Neonatal onset multisystem inflammatory disease 
PAAND - Pyrin-associated autoinflammation with neutrophilic dermatosis 
PAMI - PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome 
PAPA - PSTPIP1 arthritis, pyoderma gangrenosum, and acne  
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis 
PLD - PLCG2 dysregulation 
PLAID - PLCG2-associated antibody deficiency and immune dysregulation 
PLCG2 - Phospholipase C γ2 
POMP - proteasome maturation protein 
PRINTO - Pediatric rheumatology international trials organization 
PRAAS - Proteasome associated autoinflammatory syndrome 
PSMB 3-4,8-9 - Proteasome Subunit, β-type, 3,4,8,9 
PSTPIP1 - proline serine threonine phosphatase-interacting protein 1 
-SAPHO - synovitis, acne, pustulosis, hyperostosis, and osteitis 
SDCM - SH3BP2 deficiency with multilocular cystic disease of the mandibles. 
SH3BP2 - SH3 Domain Binding Protein2 
SAP - SLAM - associated protein  
SLE - systemic lupus erythematosus 
TNF - Tumor necrosis factor 
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TNFRSF1A - Tumor necrosis factor receptor super family 1A 
TRAPS - TNF-receptor-associated periodic syndrome 
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Table 1. Current name of the disorder (in bold) and additional names (normal 
characters) derived from the literature. The last column reports the proposed 
nomenclature for the AIDs as results of the consensus process. 
 










CINCA - Chronic infantile neurological, cutaneous 
and articular syndrome [17], NOMID - Neonatal 
onset multisystem inflammatory disease 
 
Severe 
MWS - Muckle-W lls syndrome [18] 
 
Moderate 







PRP - Familial Pityriasis rubrapilaris [30]  






SH3BP2 deficiency with multi 
locular cystic disease of the 
mandibles (SDCM) 
Familial Multilocular Cystic Disease of the Jaws 
[46] 
 
Cherubism--familial fibrous dysplasia of the jaws 
[47] 
 
CGCL - Central giant cell lesion [48] 
 
 
CRMO - Chronic recurrent multifocal 
osteomyelitis [29] 
Chronic non-bacterial osteomyelitis 
(CNO) - (when the gene is known it 
should be added) 
Majeed syndrome [26],  
Congenital dyserythropoietic anemia and chronic 
recurrent multifocal osteomyelitis [27] 
 
LIPIN2-associated disease [28] 
 










FCAS2 – Familial cold autoinflammatory 





Guadeloupe fever, NALP12 periodic fever  
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FMF - Familial Mediterranean fever (FMF)[7] (No change) 
Benign paroxysmal peritonitis [4] , Periodic disease 
[5], Armenian disease, Periodic disease "Maladie 
periodique" [6], Familial Mediterranean fever (FMF) 
[7], Recurrent polyserositis [8], Familial paroxysmal 
polyserositis [9]  
 
  
PAAND - Pyrin-associated autoinflammation 





Joint contractures, Muscle atrophy, Microcytic 
Anemia and Panniculitis Induced 
Lipodystrophy [38],  
Chronic Atypical Neutrophilic Dermatosis with 
Lipodystrophy and Elevated Temperature 
(CANDLE) Syndrome [37], Nakajo-Nishimura 
Syndrome (NNS) [39   
 















Mevalonate kinase deficiency 
(MKD) 
HIDS - Hyper IgD syndrome [15] 
Mevalonic aciduria (67) 
Mild 
Severe 
Mevalonate kinase disease (Deficiency) [13, 14]  
Dutch type periodic fever [16] (Add porokeratosis or retinitis 






Inflammatory bowel disease 
IBD - IL-10R-associated very early [32]  




NOD2 CARD15-Associated disease NOD2-associated granulomatous 
disease 
(Optional: add Blau syndrome or IBD 
according to the main clinical 
features) 
Blau syndrome [21], Early onset sarcoidosis [22], 
Familial Crohn's disease [23] 
 
 
PAPA / Pyogenic Arthritis, Pyoderma 
gangrenosum, and Acne syndrome [35] 
 
PSTPIP1-associated arthritis, 
pyoderma gangrenosum, and acne 
(PAPA) 
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PFAPA - Periodic fever, aphthous stomatitis, 
pharyngitis and adenitis 
(No change) 
Periodic fever, aphthous stomatitis, pharyngitis and 
adenitis or periodic fever aphthous pharyngitis and 
cervical adenopathy [41] 
 
Marshall's syndrome [42]  
  
  
Schnitzler syndrome [40] 
 
(No change) 





TRAPS - TNF receptor-associated periodic 
fever syndrome[3] 
(No change) 
Familial Hibernian fever [11]  
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Table 2. Results from the Delphi questionnaires for consensus on 
nomenclature 
 





Autoinflammatory diseases are clinical disorders caused by defect(s) or 
dysregulation of the innate immune system, characterized by recurrent or 
continuous inflammation (elevated APR) and by the lack of a primary 




Final names proposed for the AIDs  
CARD14-associated psoriasis 91% 
CNO: Chronic non-bacterial osteomyelitis 87% 
DIRA: Deficiency of the IL-1 receptor antagonist 96% 
DITRA: Deficiency of the IL-36 receptor antagonist 96% 
IL-10 deficiency-associated inflammatory bowel diseases 83% 
PAAD: Pyrin-associated autoinflammatory disease:  
FMF, PAAND 
88% 
MKD: Mevalonate kinase deficiency 87% 
NLRP3-AID – NLRP3-associated autoinflammatory disease 88% 
NLRP12-AID – NLRP12-associated autoinflammatory disease 88% 
NOD2-associated granulomatous diseases 83% 
PAPA: PSTPIP1-associated arthritis, pyoderma gangrenosum and acne 87% 
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis 83% 
PRAAS : Proteasome-associated autoinflammatory syndrome 84% 
Schnitzler syndrome 87% 
SDCM - SH3BP2 deficiency with multilocular cystic disease of the mandibles 94% 
TRAPS - TNF receptor-associated periodic fever syndrome 83% 
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Table 3. Recommandations for naming AIDs  
 
 
1. Try not to change wherever the name is appropriate. 
2. Avoid names of persons or geographical spread of disease (eponyms) 
3. Include the genetic basis (name of the gene) of the disease where it is known (prefer 
the name of the gene over the name of the encoded protein unless the name of the 
gene is not accurate or meaningless) 
4. Include key clinical features where appropriate 
5. Shorten the name as much as possible 
6. Choose a name that is as clear as possible 
7. In diseases where our knowledge about the pathogenesis is still limited, leave the 
previous name (PFAPA) 
8. In diseases with different phenotypes but mutations in the same gene, use a general 
"roof" name with subtypes (PAAD, NOD2).  
9. When the clinical features seemed to be "continuous" give a general name ("roof" 
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Legends to figure 
 
Figure 1 
The group of diseases associated with MEFV sequence alterations. The "roof" name 
is a general name whereas the subtypes are more specific and meaningful. 
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The group of diseases associated with MEFV sequence alterations. The "roof" name is a general name 
whereas the subtypes are more specific and meaningful.  
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Supplementary figure S1 
Literature review for the definitions of Autoinflammatory diseases using the MESH search term: 
“autoinflammatory diseases” and subsequently all names reported in Table 1. 
    





    
  Number of articles excluded  
529 
Reasons for exclusions 
• 220 were not related to the subject of 
autoinflammatory diseases 
• 63 dealt with clinical features of AIDs 
• 60 dealt with pathogenesis of AIDs 
• 48 dealt with associated diseases Gout, Behcet, 
spondyloarthropathies  
• 46 dealt with treatment of AIDs 
• 23 dealt with the inflammasome 
• 23 general overviews of AIDs 
• 18 Guidance and genetics of AIDs 
• 10 Animal studies 
• 10 Proceedings of meetings 
• 1 In Turkish language  
 
    
Final articles considered 
7 
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Table 1 Supplementary: Current name of the disorder and additional names derived from the literature. 
The last column reported the proposed  nomenclature for the AIDs as results of the consensus process. 
 
Current name of 
the disorder 
Additional names OMIM Name of the 
gene 
















Neonatal onset multisystem 
inflammatory disease 
(NOMID) 
607115   
Severe 
 Muckle-Wells syndrome 
(MWS) [18] 
191900   
Moderate 
 Familial cold 
autoinflammatory syndrome 
(FCAS) [19] 
   
Mild 
      
CARD14-associated 
disease 
 CARD14 CARD14  CARD14-associated 
psoriasis 
 Familial Pityriasis rubrapilaris 
(PRP) [30] 
    
Page 34 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
2 
 
Current name of 
the disorder 
Additional names OMIM Name of the 
gene 




 CAMPS - CARD14-mediated 
pustular psoriasis [31] 
    
      
Cherubism [45] 
 
 266270 SH3BP2 SH3BP2 SH3BP2 deficiency with 
multi locular cystic 
disease of the mandibles 
(SDCM) 
 
 Familial Multilocular Cystic 
Disease of the Jaws [46] 
    
 Cherubism--familial fibrous 
dysplasia of the jaws [47] 
    
 Central giant cell lesion 
(CGCL) [48] 
    





    Chronic non-bacterial 
osteomyelitis (CNO) (when 
the gene is known it should 
be added) 
 Majeed syndrome [26] 609628 LPIN2 LIPIN 2  
 Congenital dyserythropoietic 
anemia and chronic recurrent 
multifocal osteomyelitis [27] 
    
 LIPIN2-associated disease 
[28] 
   LPIN2-CNO 
      
DIRA 
Deficiency of the IL-1 
 612852 IL1RN IL-1Ra (No change) 
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Current name of 
the disorder 
Additional names OMIM Name of the 
gene 




receptor antagonist [24] 
      
DITRA 
Deficiency of the IL-
36R antagonist  [25] 
 614204 IL36RN IL-36Ra (No change) 




syndrome 2 [36] 
 611762 NLRP12 NLRP12 NLRP12-associated 
autoinflammatory disease  
(NLRP12-AID) 
 Guadeloupe fever     
 NALP12 periodic fever 
syndrome [36] 













MEFV Pyrin (No change) 
 Benign paroxysmal peritonitis 
[4]  
    
 Periodic disease [5]     
 Armenian disease      
 Periodic disease "Maladie 
periodique" [6]  
    
 Familial Mediterranean fever     
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Current name of 
the disorder 
Additional names OMIM Name of the 
gene 





 Recurrent polyserositis [8]     
 Familial paroxysmal 
polyserositis [9] 
    




neutrophilic dermatosis  
[10]  
    (No change) 





Hyper IgD syndrome 
[15] 
Mevalonate kinase disease 
(Deficiency) [13, 14] 
260920 MVK Mevalonate 
kinase 
Mild 
 Dutch type periodic fever [16]     
Mevalonic aciduria 
(67) 
    Severe  
     (Add porokeratosis or 
retinitis pigmentosa when 
present) 
      
     Roof name: Proteasome-
associated 
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Current name of 
the disorder 
Additional names OMIM Name of the 
gene 









Microcytic Anemia and 
Panniculitis Induced 
Lipodystrophy[38] 






 Chronic Atypical Neutrophilic 
Dermatosis with 
Lipodystrophy and Elevated 
Temperature (CANDLE) 
Syndrome [37] 
    
 Nakajo-Nishimura Syndrome 
(NNS) [39] 
    
      







 IL-10R-associated very early 
IBD [32] 
    
 Infantile colitis [33]     
      
NOD2 (CARD15)-
associated disease  
 186580 NOD2/CARD15 NOD2 Roof name: NOD2-
associated granulomatous 
disease 
(Optional: add Blau 
syndrome or IBD according 
to the main clinical features) 
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Current name of 
the disorder 
Additional names OMIM Name of the 
gene 




 Blau syndrome [21]     
 Early onset sarcoidosis [22].      
 Familial Crohn's disease [23]     











gangrenosum, and acne 
(PAPA) 
      





Periodic fever, aphthous 
stomatitis, pharyngitis and 
adenitis or periodic fever 
aphthous pharyngitis and 
cervical adenopathy [41] 
    
 Marshall's syndrome [42]     
      
Schnitzler syndrome 
[40] 
    (No change) 
 Periodic fever with urticaria 
and paraprotein (PUPAP) 
    
      
TRAPS - TNF 
receptor-associated 
periodic fever 
 142680 TNFRSF1A TNFR1 (No change) 
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Current name of 
the disorder 
Additional names OMIM Name of the 
gene 





 Familial Hibernian fever [11]     
 Familial autosomal dominant 
periodic fever [12] 
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Background: Autoinflammatory diseases (AIDs) are a relatively new family of 
disorders defined about 19 years ago. Some of them are hereditary and some 
are not.The names given to these diseases do not follow any systematic 
guidelines and sometimes the same disorder carries several names. 
Aims: The aim of this study is to refine the definition of the autoinflammatory 
diseases and to provide some conventions for their naming. We have focused 
our attention mainly on monogenetic AIDs. 
Methods: Delphi technique which enables consensus among a group of 
experts through Internet and mail communication and questionnaires - was 
employed. After achieving 100% consensus among 6 members of a steering 
committee, the questionnaire containing the AID definitions and the agreed-
upon conventions, were sent to 26 physicians and researchers working in the 
field of AIDs in order to gain broader support for the committee's proposals. 
Results: The committee proposed the following definition for AIDs 
"Autoinflammatory diseases are clinical disorders caused by defect(s) or 
dysregulation of the innate immune system, characterized by recurrent or 
continuous inflammation (elevated acute phase reactants-APR) and the lack 
of a primary pathogenic role for the adaptive immune system (autoreactive T-
cells or autoantibody production)”. Several rules were defined for guiding the 
naming of these diseases among which are: abandoning eponyms and 
preferring the name of the gene over its encoded protein. 
Conclusions: The new definition for AIDs allows inclusion of clinical 
disorders mainly associated with defects in the innate immune system. The 
new conventions propose names with clinical meaning and in some cases 
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Taxonomy is the science of naming. It is relevant to all fields of biology in which we 
name plants, animals, objects and diseases. In medicine, naming of diseases or 
syndromes has a special importance since it can give some clue about the nature of 
the clinical condition, its clinical features, pathogenesis and sometimes even an 
approach to treatment. Naming is also important for accurate and effective 
communication among different health disciplines. However, medical disorders have 
not been named in a standard way [1]. Physicians, who treat patients with a 
particular disorder or face a new clinical condition, are often the first to propose a 
name for the disease. Expert working groups may later revise the names to improve 
their usefulness.  
Names of medical disorders are often derived from one or a combination of the 
following sources: genetic basis or biochemical defect; geographic spread; or by 
eponyms. The main drawback of many names is the lack of a clinical meaning that 
could help the novice to understand the origin of the disease or recognize its clinical 
characteristics .  
The autoinflammatory diseases (AIDs) are a group of medical disorders, derived from 
defects or dysregulation of the innate immune system [2]. This family of diseases 
was established in 1999 following the identification of the genes underlying two 
recurrent fever syndromes: familial Mediterranean fever (FMF) [3,4] and TNF-
receptor-associated periodic syndrome (TRAPS) [5]. Over the last 18 years, more 
and more diseases have been classified amongst this group of disorders, some of 
which may not fit well with the classical definition of the AIDs. Moreover, many of 
them were given names with no systematic guidelines or rules. In some cases, the 
same disease carries several names (Table 1) [6-50]. This has led to a chaotic 
situation in naming these clinical disorders and has called for a better standardization 
of this field. This need is accentuated by recent progress in next generation 
sequencing techniques (NGS), which have led to an increasing capability to identify 
new genes and new syndromes, expanding the spectrum of AIDs.  
Indeed, following the International Society for Systemic Autoinflammatory Diseases 
(ISSAID) meeting in Lausanne, in 2013, a mandate was given to one of us (E B-C) to 
undertake a preliminary consensus based exercise for the following aims: a. to refine 
the definition of the "autoinflammatory diseases". b. to provide some rules and new 
proposals for naming this current group of clinical conditions and those that will be 
identified in the future.  
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In order to find the different definitions proposed for AIDs over the years, we 
searched the MEDLINE/PubMed Central® (PMC) from 1998 to January 2016, using 
the MESH search term: “autoinflammatory diseases” (supplementary Figure S1). In 
order to find the names used for each AID, we took one of their current names as 
depicted in Table 1 and searched for papers where they were first reported. Then, we 
searched for reviews on these items to find additional synonymous names Table 1 is 
based on a list of AIDs published by one of the authors (IT) [51], properly integrated 
and updated during the consensus process and finally approved  by all the steering 
committee members. Table 1 is based on a list of AIDs published by one of the 
authors (IT) [51] and gained consensus by all the steering committee members. It 
focused - mainly - on monogenic disorders. 
For choosing the best definition for AIDs and the most appropriate name for each 
AID, we have used the Delphi technique, which enables consensus among a group 
of experts through mail communication [52]. The Delphi method is essentially a 
series of questionnaires involving several steps, each of which is based on the 
results of the previous step. The process stops when consensus of at least 80% of 
the participants on each item is reached. [53] 
An ad hoc steering committee of 6 clinicians and researchers from 6 different 
countries who are working in the field of autoinflammation was established. 
The first Delphi questionnaire was built through sending broad and open-ended 
questions in order to elicit different opinions from the panelists about the current 
definitions and names of AIDs.  
Once received, the replies from the panelists were analyzed to generate a series of 
statements that were employed as the basis for follow up questionnaires that were 
sent back to the individual participants. In each subsequent questionnaire, the 
panelists were also provided with the overall results (responses) of the previous 
questionnaire from all the members. After achieving 100% consensus among the 
steering committee members, the questionnaire containing the AID definitions and 
the agreed-upon names of AIDs were sent to 26 physicians and researchers working 
in the field of AIDs around the world. They were identified in the Paediatric 
Rheumatology International Trials Organization (PRINTO) mailing list through their 
high active participation in the Eurofever registry [54, 55]. The aim of this step was to 
gain broader support for the committee's proposals and to consider changes once a 
name was rejected by or was not acceptable to more than 80% of the participants of 
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AIDs proposed definition 
The literature review disclosed 536 papers of which only 7 specifically dealt with the 
definitions of AIDs [5, 57- 62] (supplementary Figure S1). The first definition for AIDs 
was proposed by the NIH group in 1999 [5]. This definition was as follows: "The 
autoinflammatory syndromes are systemic disorders characterized by apparently 
unprovoked inflammation in the absence of high-titer autoantibodies or antigen-
specific T lymphocytes". This definition was based mainly upon the two diseases 
whose related genes had then been identified: FMF and TRAPS [3- 5]. Since in both 
diseases the flares appeared mostly spontaneous, the definition included the word 
"unprovoked". The definition stresses the lack of involvement of the adaptive immune 
system in these disorders, since no autoantibodies or autoreactive T-cells were 
involved.  
Seven years later McGonagle and McDermott suggested another definition: "AIDs 
are characterized by self-directed inflammation, whereby local factors at sites 
predisposed to disease lead to activation of innate immune cells, including 
macrophages and neutrophils, with resultant target tissue damage. For example, 
disturbed homeostasis of canonical cytokine cascades (as in the periodic fevers), 
aberrant bacterial sensing (as in Crohn's disease), and tissue micro-damage 
predispose one to site-specific inflammation that is independent of adaptive immune 
responses" [57]. The authors proposed that immunological diseases ought to be 
conceived as a continuum with “pure monogenic autoinflammatory diseases” at one 
end and “pure monogenic autoimmune diseases” at the other. This definition is 
relatively complex, but explicitly invokes innate immunity and widens the spectrum of 
AIDs.  
Later, several other definition or refinement were proposed [58-61]. In a recent study, 
de Jesus et al. provide an outstanding classification of AIDs strictly based on their 
pathophysiology [62]. However, the authors do not propose a new definition for the 
AIDs.  
Given the proliferation of AID definitions, with sometimes conflicting concepts, the 
steering committee agreed to adopt the first and original definition with minor 
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modifications: "Autoinflammatory diseases are clinical disorders caused by defect(s) 
or dysregulation of the innate immune system, characterized by recurrent or 
continuous inflammation (elevated - APR) and the lack of a primary pathogenic role 
for the adaptive immune system (autoreactive T-cells or autoantibody production).”  
This definition emphasizes the essential fact that the disorders are caused by defects 
in the innate immune system and are continuous or recurrent. The word 
"unprovoked" has been deleted since in many cases there is a trigger for the acute 
flares.  
The steering committee is aware that diseases such as PLCG2-associated antibody 
deficiency and immune dysregulation (PLAID) or Heme - oxidised IRP2 ubiquitin 
ligase1 (HOIL-1) deficiency, traditionally included among the AIDs, will not be part of 
this group, because they may contain components of the adaptive immune system 
such as autoantibodies [63]. The "Interferonopathies" include some disorders also 
manifesting autoantibodies. However, the consensus seemed to be that for disorders 
like Aicardi-Goutières Syndrome (AGS) in which nucleic acid sensing is primarily 
intracellular, autoantibodies usually play a minor role in disease pathogenesis, and 
thus the autoinflammatory designation may still be appropriate. In their recent review 
Rodero and Crow propose that “type I interferonopathies can reasonably be 
considered as autoinflammatory in origin, with ‘spill-over’ into autoimmunity in some 
cases” [64]. The group of "typical" autoimmune diseases includes disorders 
affecting primarily or only the adaptive system such as systemic lupus erythematosus 
(SLE), Hashimoto thyroiditis, DNAse deficiencies and autoimmune 
lymphoproliferative syndrome (ALPS). 
AIDs proposed nomenclature 
The current names for AIDs bring several problems and issues, which called for a 
new approach and nomenclature modification; many AIDs possess more than a 
single name (FMF - 7 different names, TRAPS - 3, etc) (Table 1 and Supplementary 
Table S1); different clinical presentations are associated with similar sequence 
alterations in the same gene eg. Muckle-Wells syndrome(MWS), familial cold 
autoinflammatory syndrome (FCAS) and Neonatal onset multisystem inflammatory 
disease (NOMID) are associated with NLRP3 gene whereas FMF and pyrin-
associated autoinflammation with neutrophilic dermatosis (PAAND) are associated 
with MEFV gene. In addition discussion arose about several topics briefly 
summarized herein: In naming AIDs should we use the name of the gene or that of 
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the encoded protein (MEFV or pyrin)? Should we include typical clinical features or 
just genetic attributes? Should historical names be retained?  
Following more than 6 cycles of Delphi questionnaires and oral discussions among 
the 6 members of the steering committee  with further involvement of the 26 AIDs 
experts around the world - a consensus of at least 80% was reached for the 
nomenclature of the diseases shown in Tables 1 and 2. 
General conventions (Table 3) 
The proposed names for AIDs have been established according to the rules and 
suggestions outlined in Table 3. 
In many diseases the course of the disease is episodic with frequent attacks and 
attack-free intervals. When the frequency of the attacks is relatively regular (as is the 
case with Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) and 
sometimes with mevalonate kinase deficiency (MKD) we preferred the term 
"periodic". When the attacks do not have a regular pattern, we suggested the word 
"recurrent”.  
In the past, both terms, “periodic” and “recurrent”, have been used interchangeably 
but now the term "periodic” remained in the names of 3 conditions only; Cryopyrin-
associated periodic fever syndrome (CAPS),TRAPS and PFAPA. In TRAPS, we 
decided to keep the original name "periodic", although its flares are recurrent rather 
than periodic. In CAPS, we propose a new name (NLRP3-AID) which does not 
contain the word “periodic since the attacks are not periodic”. Thus, we strongly 
suggest using the more appropriate terms in naming disorders in the future. 
As a general rule, we tried to use names containing etio-pathological (genetic) 
features of the disease and where appropriate or possible, to add a significant clinical 
characteristic of the syndrome. Thus, we left the name TRAPS without change, since 
it consists of its genetic etiology (mutations in TNFRSF1A gene) and characteristic 
clinical features [periodic (recurrent) fever]. On the other hand, the name hyper IgD 
syndrome (HIDS) was abandoned since it is an absolutely inaccurate name: serum 
IgD is not always elevated in these patients while it may be elevated in other AIDs. 
Therefore, this name was replaced by MKD based upon our knowledge of the gene 
involved, mevalonate kinase (MVK). In this way, a physician or researcher who 
approaches these names for the first time may have immediately a basic 
understanding of the disorder and sometimes even a clue to the potential treatment. 
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In cases where the choice was between using the name of the gene associated with 
the disease or the protein encoded by the gene, we preferred the name of the gene 
over that of the protein unless the former was meaningless. A typical example is the 
choice of NLRP3 gene over cryopyrin despite the tendency of some clinicians to stay 
with the former term CAPS. Fortunately, in many cases the name of the gene and the 
encoded protein are the same (MK, NOD2) making the choice easier. However, this 
was not the case with the MEFV gene and pyrin where the name of the protein was 
chosen, as will be discussed later. 
In our proposals for new taxonomy of AIDs, we tried to avoid the use of names of 
persons (such as Nakajo Nishimura syndrome) or geographical distribution of the 
disease (such as Guadeloupe fever) or names with unusual meaning (such as 
"Cherubism").  
Specific names (Table 1 and Supplementary Table S1)  
In the case of CAPS – which encompasses three clinical entities (FCAS, MWS, 
NOMID/CINCA), the committee has proposed using a single name; NLRP3-
associated autoinflammatory disease (NLRP3-AID). Since the various disorders 
reflect different levels of phenotypic severity of the same disease, it was suggested to 
add the adjectives: mild, moderate, and severe phenotypes, instead of using the 
historical names FCAS, MWS and CINCA/NOMID, respectively.  
In familial cold autoinflammatory syndrome 2 (FCAS2) (Guadeloupe fever), different 
families present with different phenotypes [36]. Since the gene associated with the 
disease (NLRP12) is known, the committee decided to name this syndrome NLRP12-
associated autoinflammatory disease (NLRP12-AID).  
In the case of MEFV-associated diseases, the question raised was as follows: should 
we use the old name FMF or "atypical FMF" for all syndromes associated with 
mutations in the MEFV gene even if they have totally different clinical 
manifestations? Alternatively, should we find a different way to classify these 
disorders? The committee chose to use a general name (as a "roof ") "pyrin-
associated autoinflammatory diseases" (PAAD) which includes all diseases 
associated with pyrin defects or MEFV mutations. Under this general term, there are 
subtypes of disorders with different names, according to their clinical presentation or 
genetic features, such as: PAAND, FMF, etc. [65] (Figure 1). Although it is preferred 
using the name of the gene over the name of the encoded protein, in the case of 
FMF, the protein pyrin was chosen rather than the MEFV gene. One of the reasons 
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was that the name MEFV, which was coined to denote its association with familial 
Mediterranean fever, is no longer accurate, since it may lead to totally different AIDs, 
such as PAAND and CRMO-like disorder. In addition, we did not change the name of 
familial Mediterranean fever (FMF), although sometimes it is neither familial nor 
restricted to the Mediterranean basin and in rare cases, it may even be without a 
documented fever. Most members of the steering committee thought that FMF is a 
well-known and defined entity and that changing the name would cause discomfort 
and confusion among the AID clinical community. The name FMF remained under 
the "roof" of "pyrin-associated autoinflammatory diseases" (PAAD) as a clinical entity 
which is restricted mainly to Middle Eastern patients or to patients elsewhere, whose 
disease is associated with exon 10 mutations [66].  
Regarding Mevalonate kinase disorders the committee suggested leaving MKD as a 
general name with the option of adding "mild" for those with hyper IgD syndrome and 
"severe" for those with mevalonic aciduria (67). In rare cases, where the patient with 
MKD has also retinitis pigmentosa or porokeratosis, it is suggested to mention these 
manifestations in addition to MKD (Table 1, and Supplementary Table S1 ).  
The name NOD2-associated granulomatous disease was chosen by the committee 
for the three phenotypes: Blau syndrome, familial sarcoidosis and familial Crohn's 
disease. Since all these syndromes are characterized by granulomas, this feature 
was included in the name. Nevertheless, an option was offered to add IBD in cases 
where the intestines are the main site of involvement eg. NOD2-associated 
granulomatous IBD (formerly called familial Crohn's disease). 
The name for CRMO was replaced by the name chronic non-bacterial osteomyelitis 
CNO. The reason for that was the presence of many cases where the disease was 
neither recurrent nor multifocal. Furthermore, the new name emphasizes the main 
feature of the disease, non-bacterial osteomyelitis. Since this clinical entity may be 
associated with mutations in various genes, it is optional to add the name of the gene 
when it is known. For example in case the gene involved is LPIN2 it can be marked 
as LPIN2-CNO (previously known as Majeed’s syndrome). In adults, patients with 
sporadic CNO are usually diagnosed with SAPHO, a symptom complex of Synovitis, 
Acne, Pustulosis, Hyperostosis, and Osteitis [68]. 
Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
syndrome (CANDLE syndrome) gained a new name: PSMB8-PRAAS - where 
PSMB8 stands for Proteasome Subunit Beta 8 and PRAAS for  PRoteasome-
Associated Autoinflammatory Syndrome. This name replaces also the eponym 
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Nakajo Nishimura syndrome, and JMP which stands for Joint contractures, Muscle 
atrophy, microcytic anemia and Panniculitis-induced lipodystrophy. The name 
PSMB8-PRAAS consists of the genetic etio-pathology of the disorder but does not 
include any clinical feature of the disease.  
CARD14-associated disease is usually characterized by psoriasis with or without 
pustulosis. Therefore, the name was refined to be CARD14-associated psoriasis. 
Since the 3 variants of IL-10 deficiency are always associated with inflammatory 
bowel disease, the committee proposed a single name as IL-10 deficiency-
associated IBD. 
The names; deficiency of the interleukin 1 receptor antagonist (DIRA), deficiency of 
the interleukin 36 receptor antagonist (DITRA), pyogenic arthritis, pyoderma 
gangrenosum, and acne (PAPA) and PFAPA remained unchanged since they 
already conform to our naming conventions. However, the letter P in the abbreviation 
"PAPA" now stands for the name of the gene PSTPIP1 rather than “Pyogenic” and, 
therefore, the new name is "PSTPIP1-associated arthritis, pyoderma gangrenosum 
and acne" (PAPA). 
The name "Cherubism" was derived from the Biblical "cherub" (plural cherubim) who 
has four faces of different species and several pairs of wings,. For most physicians 
this name does not mean much and therefore, the committee proposed the name 
SH3BP2 deficiency with multilocular cystic disease of the mandibles (SDCM). This 
name gives the etio-pathologic basis of the syndrome with the main clinical feature of 
fibrous dysplasia of the mandibles. 
Finally, the name “Schnitzler syndrome” also remained as an historical one, since its 
pathogenesis is still obscure and its relationship with NLRP3 mutations has not been 
established [69]. A proposal to convert the name of the syndrome to a clinical 
description: "late onset gammopathy with recurrent urticaria and fever" (LOGRUF) 
did not gain support from most of the committee members. 
Discussion  
The definition of autoinflammatory diseases has changed over the years in order to 
accommodate the new diseases discovered since 1999 – the year the term was first 
proposed [2, 5, 57-61]. Widening the scope and spectrum of definition of AIDs 
resulted in the inclusion of disorders with additional defects in the adaptive immune 
system such as PLAID or HOIL-1 deficiency. Most defects in the immune system 
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may affect primarily either the innate or the adaptive arm. However, it is becoming 
increasingly obvious that the innate immune system almost always has an effect on 
the adaptive system. This leads to the situation that there are disorders that do not fit 
neatly into the "pure" autoinflammatory or autoimmune categories, and reside 
actually in a "grey zone" between these two groups. In order to include these 
disorders with the typical AIDs under the same "rafter", Peckham et al. offered the 
term "Auto-inflammatory-immune diseases" [70]. We believe that this new name may 
lead to confusion since all the disorders caused or related to defects in the immune 
system can be classified under this wide term with no clear categorization. The 
interferonopathies are clinical disorders caused by defects in the innate response, 
leading to inflammation after DNA sensing. The activation of cells of the adaptive 
immunity is a secondary effect of this condition and seems to play a minor role in 
their pathogenesis. Therefore, they may create the bridge which fits the concept that 
the autoinflammatory diseases, and the autoimmune diseases are actually in the 
same spectrum of immune disorders. This continuum model is further supported by 
the recent discovery of the innate lymphoid cells (ILCs). These cells are defined by 
differential expression of cell-surface markers and are activated by neuropeptides, 
cytokines and other alarmins [71]. Their specialized distribution in lymphoid and non-
lymphoid tissues, coupled with their functional heterogeneity, has provoked a 
fundamental reassessment of how they integrate innate and adaptive immune 
responses. 
As already mentioned - many of the current names of AIDs were not appropriate, 
inaccurate or lack any clinical meaning. Therefore, an attempt to establish new 
conventions for naming them was really needed.  
The conventions (Table 3), and the ensuing proposals (Table 1, and Supplementary 
Table S1), call for using the name of the gene associated with the disease when it is 
known rather than the encoded protein. In these cases, demonstration of functional 
significance of the identified sequence alteration is mandatory.The main advantage 
of using the name of the gene is that such a name gives the physician a clue about 
the pathogenesis of the disease and sometimes even about a potential treatment. 
Moreover, it may allow definite diagnosis using genetic testing. However, it should be 
borne in mind that including the gene in the name of the disease may pose a problem 
in cases where the clinical features of the patient are compatible with a certain 
diagnosis while no expected sequence alteration is found. Thus, the main drawback 
of using the name of the gene is that definite diagnosis can be made only by genetic 
testing.  
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In cases where the clinical features and the genetic testing results are in accord, the 
name is appropriate and the diagnosis is correct and definite. When there is a clearly 
pathogenic mutation but the clinical features are completely incompatible with the 
expected diagnosis, one should consider a different disease with a different name. 
This situation is illustrated by the case of the MEFV mutation S242R, which causes 
neutrophilic dermatosis. The name of this disease is not "FMF" or "atypical FMF" 
despite the fact that there are MEFV mutations - but "pyrin-associated 
autoinflammation with neutrophilic dermatosis (PAAND)". Similar approach may be 
applied in the case of PSTPIP1 with the new mutation and different clinical 
presentation [72]. We suggest here a "roof" name : PSTPIP1-associated 
autoinflammatory diseases with two subtypes: PAPA and PAMI (PSTPIP1-
associated myeloid-related proteinemia inflammatory syndrome). However, we 
cannot add this approach to Table 1 since it was not discussed in the Delphi 
questionnaires among the large group of participants 
When the clinical features are typical for a certain disease ( for example FMF) and 
yet no genetic support for this diagnosis is found, one can denote this medical 
condition as an FMF-like disease. However, a better choice would be to leave the 
case as an undefined AID until mutations in other genes are found or additional 
explanations for the disease are given. The reason is that clinical features typical for 
one AID may be associated with mutations in different genes. For example, in 
arecent  report, Karacan et al. described two Turkish families in whom 4 patients 
presented with typical clinical features of FMF [73]. Genetic analysis performed in 
these patients failed to show MEFV mutations. However, total exon sequencing 
revealed that two patients were homozygous for mutations in MVK and the two other 
patients carried mutations in the TNFRSF1A gene. These cases illustrate the 
difficulties in making a diagnosis of AID based upon clinical features only and justify 
the proposal to use the gene in naming AIDs wherever it is known. 
 The way we proposed naming CAPS and FCAS 2 namely NLRP3-associated 
autoinflammatory disease (NLRP3-AID) and NLRP12-AID respectively may pave the 
way for naming future disorders to be discovered or identified among the other 
members of the large family of NOD–like receptors (NLRs).. Similarly, PSMB8-
PRAAS, the name which was proposed to replace CANDLE syndrome, JMP and 
NNS, may also serve as an example for naming additional proteasome associated 
diseases to be discovered, just by changing their number. In fact, Brehm et al. 
recently described several cases that carry mutations in PSMA3 (encodes α7), 
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PSMB4 (encodes β7), PSMB9 (encodes β1i), and proteasome maturation protein 
(POMP) [74]. 
Unfortunately, the current study did not include  many other monogenic AIDs such as 
those associated with ADA2, NLRC4, NLRP1 genes or X-linked inhibitor of apoptosis 
(XIAP) deficiency and (SLAM)-associated protein (SAP) deficiency (75). The reason 
is that we limited ourselves mainly to the basic list reported by Toiutou et al.(51). 
However, we hope that the conventions we propose herein may help modifying 
names of additional diseases - old and new – when, they do not follow the rules 
suggested. 
For this project we used the Delphi technique which allowed discussion via an ad hoc 
web-based system developed by the PRINTO staff under the supervision of NR who 
has an extensive expertise in consensus formation methodologies. The PRINTO 
system allowed remote interaction between the participants who had the possibility to 
share written comments with the other participants in a transparent and traceable 
way. A limitation of the current work was that for lack of funding we could not conduct 
a formal nominal group technique (NGT) which is a guided face-to-face discussion 
and interaction, among small groups of experts. However, the additional discussion 
of the ad hoc steering committee consensus proposal by another group of 26 
worldwide experts in the field of AIDs further strengthens these proposals. 
In conclusion, the currently proposed rules for nomenclatures of AIDs are expected 
to allow a better organization of these groups of immune diseases. However, 
taxonomy is a dynamic process and some of the proposed names may be changed 
in the future as we gain a better knowledge about their pathogenesis. The proposed 
taxonomy may gain a broader consensus following an effective communication with 
other societies such as the International Union of Immunological Societies Expert 
Committee (IUIS).  
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Glossary - Abbreviations 
 
 
AGS - Aicardi-Goutières Syndrome 
 
AIDs - Autoinflammatory diseases 
 
AIMDs - Autoimmune diseases 
 
ALPS - Autoimmune lymphoproliferative syndrome 
 
 
APR - Acute phase reactant 
 
CANDLE - Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated 
temperature syndrome 
 
CAPS - Cryopyrin-associated periodic fever syndrome 
 
CARD - Caspase recruitment domain family member 
CINCA- Chronic infantile neurologic, cutaneous and articular syndrome  
CNO - Chronic non-bacterial osteomyelitis 
CRMO -Chronic recurrent multifocal osteomyelitis 
ADA2 - adenosine deaminase 2 
DIRA - Deficiency of the interleukin 1 receptor antagonist 
 
DITRA - Deficiency of the interleukin 36 receptor antagonist 
 
FCAS - Familial cold autoinflammatory syndrome  
FMF - Familial Mediterranean fever  
HIDS - Hyper-IgD with periodic fever syndrome 
 
HOIL -1 - Heme - oxidised IRP2 ubiquitin ligase 1 
 
IBD - Inflammatory bowel disease 
ISSAID - International society for systemic autoinflammatory diseases  
 
JMP - Joint contractures, muscle atrophy, microcytic anemia and panniculitis-induced 
lipodystrophy. 
LOGRUF - Late onset gammopathy with recurrent urticarial and fever 
MEFV - Mediterranean fever 
MK- Mevalonate kinase 
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MKD - Mevalonate kinase deficiency 
MVK - Mevalonate kinase 
MWS - Muckle-Wells syndrome; 
NALP 12- NACHT, LRR and PYD domains-containing protein 1 
NGS - New generation sequencing 
NLR - NOD-like receptor 
NLRC4 - NOD-like receptor with CARD containing 4 
NLRP - NOD-like receptor with LRR (Leucine rich repeat), and PYD domain;  
NOD - Nucleotide-binding oligomerization domain;  
NOMID - Neonatal onset multisystem inflammatory disease 
PAAND - Pyrin-associated autoinflammation with neutrophilic dermatosis 
PAMI - PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome 
PAPA - PSTPIP1 arthritis, pyoderma gangrenosum, and acne  
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis 
PLD - PLCG2 dysregulation 
PLAID - PLCG2-associated antibody deficiency and immune dysregulation 
PLCG2 - Phospholipase C γ2 
POMP - proteasome maturation protein 
PRINTO - Pediatric rheumatology international trials organization 
PRAAS - Proteasome associated autoinflammatory syndrome 
PSMB 3-4,8-9 - Proteasome Subunit, β-type, 3,4,8,9 
PSTPIP1 - proline serine threonine phosphatase-interacting protein 1 
-SAPHO - synovitis, acne, pustulosis, hyperostosis, and osteitis 
SDCM - SH3BP2 deficiency with multilocular cystic disease of the mandibles. 
SH3BP2 - SH3 Domain Binding Protein2 
SAP - SLAM - associated protein  
SLE - systemic lupus erythematosus 
TNF - Tumor necrosis factor 
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TNFRSF1A - Tumor necrosis factor receptor super family 1A 
TRAPS - TNF-receptor-associated periodic syndrome 




Page 65 of 71
https://mc.manuscriptcentral.com/ard





























































Confidential: For Review Only
26 
 
Table 1. Current name of the disorder (in bold) and additional names (normal 
characters) derived from the literature. The last column reports the proposed 
nomenclature for the AIDs as results of the consensus process. 
 










CINCA - Chronic infantile neurological, cutaneous 
and articular syndrome [17], NOMID - Neonatal 
onset multisystem inflammatory disease 
 
Severe 
MWS - Muckle-Wells syndrome [18] 
 
Moderate 







PRP - Familial Pityriasis rubrapilaris [30]  






SH3BP2 deficiency with multi 
locular cystic disease of the 
mandibles (SDCM) 
Familial Multilocular Cystic Disease of the Jaws 
[46] 
 
Cherubism--familial fibrous dysplasia of the jaws 
[47] 
 
CGCL - Central giant cell lesion [48] 
 
 
CRMO - Chronic recurrent multifocal 
osteomyelitis [29] 
Chronic non-bacterial osteomyelitis 
(CNO) - (when the gene is known it 
should be added) 
Majeed syndrome [26],  
Congenital dyserythropoietic anemia and chronic 
recurrent multifocal osteomyelitis [27] 
 
LIPIN2-associated disease [28] 
 










FCAS2 – Familial cold autoinflammatory 





Guadeloupe fever, NALP12 periodic fever  
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FMF - Familial Mediterranean fever (FMF)[7] (No change) 
Benign paroxysmal peritonitis [4] , Periodic disease 
[5], Armenian disease, Periodic disease "Maladie 
periodique" [6], Familial Mediterranean fever (FMF) 
[7], Recurrent polyserositis [8], Familial paroxysmal 
polyserositis [9]  
 
  
PAAND - Pyrin-associated autoinflammation 





Joint contractures, Muscle atrophy, Microcytic 
Anemia and Panniculitis Induced 
Lipodystrophy [38],  
Chronic Atypical Neutrophilic Dermatosis with 
Lipodystrophy and Elevated Temperature 
(CANDLE) Syndrome [37], Nakajo-Nishimura 
Syndrome (NNS) [39   
 















Mevalonate kinase deficiency 
(MKD) 
HIDS - Hyper IgD syndrome [15] 
Mevalonic aciduria (67) 
Mild 
Severe 
Mevalonate kinase disease (Deficiency) [13, 14]  
Dutch type periodic fever [16] (Add porokeratosis or retinitis 






Inflammatory bowel disease 
IBD - IL-10R-associated very early [32]  




NOD2 CARD15-Associated disease NOD2-associated granulomatous 
disease 
(Optional: add Blau syndrome or IBD 
according to the main clinical 
features) 
Blau syndrome [21], Early onset sarcoidosis [22], 
Familial Crohn's disease [23] 
 
 
PAPA / Pyogenic Arthritis, Pyoderma 
gangrenosum, and Acne syndrome [35] 
 
PSTPIP1-associated arthritis, 
pyoderma gangrenosum, and acne 
(PAPA) 
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PFAPA - Periodic fever, aphthous stomatitis, 
pharyngitis and adenitis 
(No change) 
Periodic fever, aphthous stomatitis, pharyngitis and 
adenitis or periodic fever aphthous pharyngitis and 
cervical adenopathy [41] 
 
Marshall's syndrome [42]  
  
  
Schnitzler syndrome [40] 
 
(No change) 





TRAPS - TNF receptor-associated periodic 
fever syndrome[3] 
(No change) 
Familial Hibernian fever [11]  
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Table 2. Results from the Delphi questionnaires for consensus on 
nomenclature 
 





Autoinflammatory diseases are clinical disorders caused by defect(s) or 
dysregulation of the innate immune system, characterized by recurrent or 
continuous inflammation (elevated APR) and by the lack of a primary 




Final names proposed for the AIDs  
CARD14-associated psoriasis 91% 
CNO: Chronic non-bacterial osteomyelitis 87% 
DIRA: Deficiency of the IL-1 receptor antagonist 96% 
DITRA: Deficiency of the IL-36 receptor antagonist 96% 
IL-10 deficiency-associated inflammatory bowel diseases 83% 
PAAD: Pyrin-associated autoinflammatory disease:  
FMF, PAAND 
88% 
MKD: Mevalonate kinase deficiency 87% 
NLRP3-AID – NLRP3-associated autoinflammatory disease 88% 
NLRP12-AID – NLRP12-associated autoinflammatory disease 88% 
NOD2-associated granulomatous diseases 83% 
PAPA: PSTPIP1-associated arthritis, pyoderma gangrenosum and acne 87% 
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis 83% 
PRAAS : Proteasome-associated autoinflammatory syndrome 84% 
Schnitzler syndrome 87% 
SDCM - SH3BP2 deficiency with multilocular cystic disease of the mandibles 94% 
TRAPS - TNF receptor-associated periodic fever syndrome 83% 
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Table 3. Recommandations for naming AIDs  
 
 
1. Try not to change wherever the name is appropriate. 
2. Avoid names of persons or geographical spread of disease (eponyms) 
3. Include the genetic basis (name of the gene) of the disease where it is known (prefer 
the name of the gene over the name of the encoded protein unless the name of the 
gene is not accurate or meaningless) 
4. Include key clinical features where appropriate 
5. Shorten the name as much as possible 
6. Choose a name that is as clear as possible 
7. In diseases where our knowledge about the pathogenesis is still limited, leave the 
previous name (PFAPA) 
8. In diseases with different phenotypes but mutations in the same gene, use a general 
"roof" name with subtypes (PAAD, NOD2).  
9. When the clinical features seemed to be "continuous" give a general name ("roof" 
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Legends to figure 
 
Figure 1 
The group of diseases associated with MEFV sequence alterations. The "roof" name 
is a general name whereas the subtypes are more specific and meaningful. 
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